Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy

Br J Haematol. 2009 May;145(3):369-72. doi: 10.1111/j.1365-2141.2009.07645.x. Epub 2009 Mar 5.

Abstract

This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P < 0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Hodgkin Disease / diagnostic imaging*
  • Hodgkin Disease / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Positron-Emission Tomography*
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Radiopharmaceuticals*
  • Remission Induction
  • Retrospective Studies
  • Salvage Therapy / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18